Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer

Article Link: Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer

30 March 2020 — AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC)…

Source: FDA New Drug Approvals